<DOC>
	<DOCNO>NCT02047539</DOCNO>
	<brief_summary>The primary objective study determine whether aspirin effective alleviating symptom clinical high risk ( CHR ) syndrome psychosis . The investigator aim determine whether may delay prevent onset psychosis currently experience CHR symptom . As secondary measure investigator aim collect laboratory study inflammation marker genetic sample determine whether certain genetic profile correlate risk psychosis , response aspirin treatment .</brief_summary>
	<brief_title>Randomized Controlled Trial Aspirin v Placebo Treatment Pre-psychosis</brief_title>
	<detailed_description>Patients randomly assign either active treatment ( aspirin ) placebo .</detailed_description>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>Age 19 35 Must SIPS interview CHR subject must meet least one 3 CHR syndrome define SIPS Must demonstrate adequate decisional capacity Under age 19 Have preexist gastrointestinal disease , heart disease Have kidney disease Taking nonsteroidal antiinflammatory medication Hypersensitive NSAID ( nonsteroidal antiinflammatory medication ) Have coexist unstable major medical illness Are pregnant breastfeed Consume 2 drink alcohol per day Have blood clotting disorder Are take ACE inhibitor , acetazolamide , anticoagulant , anticonvulsant , beta blocker , diuretic , methotrexate , oral hypoglycemic uricosuric agent Have history substance abuse past three moth dependence past 6 month</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>